Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities.

"Disclosure Jean Doucet has received occasional fees, either personally or institutionally, for the activities of speaking or scientific advising from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim. Pierre Gourdy has received occasional fees, either personally or institutionally, for the activities of speaking, scientific advising, or clinical research from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Organon, Pfizer, and Sanofi. Laurent Meyer has received occasional fees, either personally or institutionally, for the activities of speaking, scientific advising, or clinical research from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Merck Sharp & Dohme, Pfizer, Servier, Medtronic, and Isis Diabète. Nabil Benabdelmoumene has received occasional fees, either personally or institutionally, from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Eli Lilly. Isabelle Bourdel-Marchasson has received occasional fees from Novo-Nordisk for activities of speaking or scientific advising. The authors report no other conflicts of interest in this work."

"This article was funded by Novo Nordisk SAS, France."